Ellex to Boost Production of iTrack Microcatheters to 50 Thousand a Year

September 8, 2017: By Jon Swedien
Ellex iTrack microcatheter

Ellex iTrack microcatheter

Ellex Medical Lasers Limited will increase the production of its iTrack canaloplasty microcatheter from 20 thousand annually to 50 thousand, the Australian company announced Sept. 4.

The company is expanding and upgrading its manufacturing facility in Fremont, California. Ellex plans to complete the expansion by July 2018.

In July, Ellex increased production capacity at the Fremont site to 20 thousand units per year from 10 thousand, the company said.

Ellex said it sold about 10 thousand iTrack devices in its 2017 fiscal year that ended June 30.

Meanwhile, Ellex said it has already begun planning for a third production increase that would enable the plant to produce upward of 100 thousand units per year.

In December 2016, the company sold shares to raise $10.3 million to support sales of the iTrack in the US and China.

The Centers for Medicare and Medicaid Services in November 2016 increased the reimbursement available to ASCs purchasing and using the iTrack to $1,747 per procedure in 2017, up from $976 in 2016.

In canaloplasty, the iTrack is inserted into Schlemm’s canal, where it can open or dilate the full 360 degrees of Schlemm’s canal.

Ellex acquired the iTrack in 2014.

Headquartered in Adelaide, Australia, Ellex offers ophthalmic lasers and devices to treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, and age-related macular degeneration.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023